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DOI 10.1186/s13019-015-0226-9RESEARCH ARTICLE Open AccessCustodiol-N, the novel cardioplegic solution
reduces ischemia/reperfusion injury after
cardiopulmonary bypass
Gábor Veres1,2*, Tamás Radovits1,2, Béla Merkely2, Matthias Karck1 and Gábor Szabó1Abstract
Backgrounds: On the basis of Custodiol preservation and cardioplegic solution a novel cardioplegic solution was
developed to improve the postischemic cardiac and endothelial function. In this study, we investigated whether its
reduced cytotoxicity and its ability to reduce reactive oxygen species generation during hypoxic condition have
beneficial effects in a clinically relevant canine model of CPB.
Methods: 12 dogs underwent cardiopulmonary bypass with 60 minutes of hypothermic cardiac arrest. Dogs were
divided into 2 groups: Custodiol (n = 6) and Custodiol-N (n = 6) (addition of L-arginin, N-α-acetyl-L-histidine and
iron-chelators: deferoxamine and LK-614). Left ventricular hemodynamic variables were measured by a combined
pressure-volume conductance catheter at baseline and after 60 minutes of reperfusion. Coronary blood flow,
myocardial ATP content, plasma nitrate/nitrite and plasma myeloperoxidase levels were also determined.
Results: The use of Custodiol-N cardioplegic solution improved coronary blood flow (58 ± 7 ml/min vs. 26 ± 3 ml/min)
and effectively prevented cardiac dysfunction after cardiac arrest. In addition, the myocardial ATP content
(12,8 ± 1,0 μmol/g dry weight vs. 9,5 ± 1,5 μmol/g dry weight) and plasma nitrite (1,1 ± 0,3 ng/ml vs. 0,5 ± 0,2 ng/ml)
were significantly higher after application of the new cardioplegic solution. Furthermore, plasma myeloperoxidase level
(3,4 ± 0,4 ng/ml vs. 4,3 ± 2,2 ng/ml) significantly decreased in Custodiol-N group.
Conclusions: The new HTK cardioplegic solution (Custodiol-N) improved myocardial and endothelial function after
cardiopulmonary bypass with hypothermic cardiac arrest. The observed protective effects imply that the Custodiol-N
could be the next generation cardioplegic solution in the protection against ischemia-reperfusion injury in cardiac
surgery.
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injuryBackground
The development of cardioplegic solutions was one of
the major advances in cardiac surgery that allowed sur-
geons to extend period of ischemic arrest over 3 hours
to perform complex surgical procedures without adversely
affecting myocardial function. Among cardioplegic solu-
tions, Custodiol is unique because it could be used for
myocardial protection in complex cardiac surgery and for
organ transplantation in transplant surgery. Furthermore,* Correspondence: gaborveres@yahoo.com
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unless otherwise stated.Custodiol is attractive for longer cardiac surgery proce-
dures, because it is administered as a single dose and is
proved to offer myocardial protection for a period of up to
four hours [1,2]. Robinson et al. [3] examined the method
of myocardial protection used by North-American sur-
geons and they showed that 98% of the surgeons used
cardioplegic arrest and that 72% of them used blood car-
dioplegia, 22% crystalloid cardioplegia. In the past, several
clinical studies compared the effects of Custodiol and
blood cardioplegia on myocardial injury and none of them
demonstrated better cardiac or endothelial function [4].
Nevertheless, a recent study demonstrated that one singlehis is an Open Access article distributed under the terms of the Creative
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antegrade cold blood cardioplegia in protecting the myo-
cardium [5]. Interestingly, Scrascia et al. [6] found that
Custodiol provided an improved cardiac protection in lon-
ger ischemic times when compared to blood cardioplegia.
Recent patient demographic changes, with surgeons
operating on older and sicker patients who have more
severe disease, potentially requires a more prolonged is-
chemia, hence, an improved myocardial and endothelial
protection would be of benefit.
Although, hypothermic cardiac arrest is a widely ac-
cepted protective concept, recently, it has been shown
that cold temperature and ischemia/ reperfusion may
lead to definitive myocyte and endothelial injury mainly
mediated by an iron-dependent formation of reactive
oxygen species (ROS). Based on novel insights in cold-
induced cell and tissue injury [7,8], we have recently de-
veloped an improved new modification of the former
Custodiol solution, which proved to be of superior qual-
ity in cell culture experiments as well as preservation of
liver and lung [7,9-12]. In our previous studies in small
animals [13,14], several Custodiol-based cardioplegic
solutions were also tested in vitro as well as in vivo
to obtain the ideal composition of a new cardioplegic
solution. In our previous investigations, we demon-
strated the best cardioprotective effect of Custodiol-N
(composition of Custodiol-N see Table 1.) among the
new Cusodiol-based cardioplegic solutions against ische-
mia/reperfusion injury [13,14].Table 1 Compounds of evaluated cardioplegic solutions
Compounds of evaluated cardioplegic solutions


















Composition of the clinically used Custodiol and Custodiol-N solution.Based on the reassuring results of the aforementioned
studies we planned a preclinical, experimental study to
examine the efficacy and the safety of the newly devel-
oped cardioplegic solution (Custodiol-N) compared to
the Custodiol solution on cardiac and endothelial func-
tion in a clinically relevant canine model of cardiopul-
monary bypass.
Methods
Animals and experimental groups
Twelve dogs (foxhounds) weighing 21 to 34 kg (25.5 ±
1.4 kg) were used in this experiment. All animals re-
ceived humane care in compliance with the Principles of
Laboratory Animal Care formulated by the National
Society for Medical Research and the Guide for the Care
and Use of Laboratory Animals prepared by the Institute
of Laboratory Animal Resources and published by the
National Institutes of Health (NIH Publication No. 86–23,
revised 1996). The experiments were approved by the
Ethical Committee of the Land Baden-Württemberg
for Animal Experimentation. After the dogs were ran-
domly assigned to the experimental groups, dogs were
divided into 2 groups: Custodiol (n = 6) and Custodiol-N
(n = 6).
General management and cardiopulmonary bypass
The dogs were premedicated with propionylpromazine
and anesthetized with pentobarbital (15 mg/kg initial
bolus and then 0.5 mg/kg/h i.v.), paralyzed with pancur-
onium bromide (0.1 mg/kg as a bolus and then 0.2 mg/
kg/h i.v.), and endotracheally intubated. The dogs were
ventilated with a mixture of room air and O2 (FiO2 = 60%)
at a frequency of 12–15/min and a tidal volume starting at
15 ml/kg/min. The settings were adjusted to maintain
arterial partial carbon dioxide pressure levels between 35
and 40 mmHg. The femoral artery and vein were cannu-
lated to record aortic pressure (AoP) and to take blood
samples for the analysis of blood gases, electrolytes, pH
and further biochemical measurements (see below). Basic
intravenous volume substitution was carried out with
Ringer solution (1 ml/min/kg). According to the values of
potassium, bicarbonate, and base excess, substitution in-
cluded administration of potassium chloride and sodium
bicarbonate (8.4%). Neither catecholamines nor other hor-
monal or pressor substances were administered. After left
anterolateral thoracotomy in the fourth intercostal space
and pericardiotomy, the great vessels were dissected. After
systemic anticoagulation with sodium heparin (300 U/kg),
the left subclavian artery was cannulated for arterial perfu-
sion. The venous cannula was placed in the right atrium.
The extracorporeal circuit consisted of a heat exchanger, a
venous reservoir, a roller pump, and a membrane oxy-
genator primed with Ringer lactate solution (1000 ml)
supplemented with heparin (150 U/kg) and 20 ml sodium
Table 2 Haemodynamic and biochemical parameters
Before CBP After CPB
Custodiol Custodiol-N Custodiol Custodiol-N
HR (1/min) 122.5 ± 8.1 144.3 ± 8.4 130.1 ± 4.6 157.5 ± 13.1
MAP (mmHg) 89 ± 3 79 ± 5 77 ± 11 67 ± 3
CO (l/min) 2.1 ± 3.9 2.3 ± 0.4 1.9 ± 0.2 2.3 ± 0.2
CBF (ml/min) 41.3 ± 6.1 44.5 ± 3.8 26.2 ± 2.8# 58 ± 7.0*
MPO (ng/ml) 0.9 ± 0.3 1.1 ± 0.1 4.3 ± 2.2# 3.4 ± 0.4#*
Nitrite (ng/ml) 1.2 ± 0.3 1.6 ± 0.3 0.5 ± 0.2# 1.1 ± 0.3*
HR: heart rate, MAP: mean arterial pressure, CO: cardiac output, CBF: coronary
blood flow, MPO: plasma myeloperoxidase. All values are given as mean ± SEM.
*: p < 0.05 vs. Custodiol, #: p < 0.05 vs. baseline.
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temperature was cooled to 28°C. After crossclamping of
the aorta, the heart was arrested with different cardiople-
gic solutions based on the actual protocol (Custodiol,
Custodiol-N). During cardiac arrest the pump flow was
set at 100 ml/kg/min to maintain perfusion pressure above
a value of 35–40 mmHg at any time point, and alpha-stat
management was applied. Twenty minutes before cross-
clamp removal, rewarming was initiated. After 60 min of
cardiac arrest, the aorta was declamped, and the heart was
reperfused with normothermic blood in the bypass circuit.
If necessary, ventricular fibrillation was counteracted with
cardioversion of 40 J. Ventilation was restarted with 100%
oxygen. After a total time of 90 minutes the animals were
weaned from CPB. All animals were weaned from CPB
without inotropic support 20 min after the release of the
aortic cross clamp. Each animal of the CPB groups under-
went 90 min of CPB with 60 min of cardiac arrest and
60 min of reperfusion.
Measurements of cardiac and coronary vascular function
in vivo
Left ventricular systolic and diastolic pressures and
volumes were measured by a combined 6 F Millar
pressure-volume conductance catheter with 6 mm
spacing, which was inserted via the apex. Stroke vol-
ume (SV) was calculated from the integrated flow
signal measured by an aortic ultrasonic flow probe
(Transonic Systems Inc., Ithaca, NY, USA) and was
used to calibrate the volume signal from the conduct-
ance catheter. Parallel conductance was estimated by
rapid injection of 1 ml of hypertonic saline into the
left atrium. The pressure and volume signal provided
by the conductance catheter was registered continu-
ously and computed by the IOX software (EMKA
Technologies, Paris, France). Vena cava occlusions were
performed to obtain a series of pressure–volume loops.
The slope (Ees) of the left ventricular end-systolic pres-
sure–volume relationship and preload recruitable stroke
work (PRSW) were calculated as load-independent indices
of myocardial contractility.
Coronary blood flow was measured on the left an-
terior descending (LAD) coronary artery with a peri-
vascular ultrasonic flow probe (Transonic Systems
Inc., Ithaca, NY, USA). Endothelium-dependent coronary
vasodilatation was assessed after intracoronary admin-
istration of a single bolus of acetylcholine (ACh, 10−7 mol)
and endothelium-independent vasodilatation after admin-
istration of sodium-nitroprusside (SNP, 10−4 mol). The
vasoresponse was expressed as percentage change of CBF.
At the end of the experiments left ventricular myocardial
tissue samples were taken and immediately immersed in
fluid nitrogen (−196°C) and stored frozen at −80°C until
the biochemical measurements.Biochemical measurements
For determination of the myocardial energetic state
myocardial adenosine triphosphate (ATP), adenosine di-
phosphate (ADP), and adenosine monophosphate (AMP)
contents were assessed from myocardial tissue with stand-
ard photometry using an enzyme-kinetic assay.
Plasma nitrate/nitrite levels (as an index of in vivo
total NO-production) were determined by a colorimetric
assay according to the Griess-method using a commer-
cial kit (Cayman Chemical Co., Ann Arbor, MI, USA).
Plasma myeloperoxidase level (as a marker for sys-
temic inflammation and leukocyte activation) was mea-
sured by enzyme linked immunosorbent assay (ELISA)
using a commercial kit (EMD Biosciences Inc. La Jolla
CA, USA).
Drugs
Acetylcholine (ACh) and sodium nitroprusside (SNP) were
from Sigma-Aldrich, Germany. Custodiol and Custodiol-N
were obtained from Dr. Franz Köhler Chemie GmBH,
Alsbach-Hähnlein, Germany.
Statistical analysis
All measurements were performed before cardiopulmo-
nary bypass and after 60 min of reperfusion. All values
were expressed as mean ± standard error of the mean
(SEM) or standard deviation (SD). A paired t-test was
used to compare two means within a group (comparison
of “before” and “after” values). Means between the groups
were compared by an unpaired two-sided Student’s t-test
(comparison of Custodiol and Custodiol-N groups). A
probability value less than 0.05 was considered statistically
significant. In the figures only the significances between
the groups were indicated.
Results
Haemodynamics
Heart rate (HR), mean arterial pressure (MAP), cardiac
output (CO) and coronary blood flow (CBF) are shown
in Table 2. Baseline heart rate was identical in the
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after CPB. CO and CBF were comparable in both groups at
baseline and CO remained unchanged in both groups
after CPB. After 60 min of reperfusion, CBF was signifi-
cantly higher in the Custodiol-N group when compared to
Custodiol.
Left ventricular function
Left ventricular function was similar in both groups at
baseline (Figure 1). Myocardial contractility - character-
ized by the load-independent indexes Ees (slope of
end-systolic pressure-volume relationship (ESPVR) and
preload recruitable stroke work (PRSW) (Figure 1) -showed
a significant decrease (p < 0.05) after extracorporal circu-
lation and reperfusion in the Custodiol group while it
remained unchanged in the Custodiol-N group.Figure 1 Changes of the slope of (A) left ventricular end-systolic pres
recruitable stroke work (PRSW) before and after cardiopulmonary byp
of (C) left ventricular end-systolic pressure volume relationship (ESPVR) and
cardiopulmonary bypass and 60 minutes of reperfusion. All values are giveEndothelial function in vivo
Coronary blood flow was similar in both groups before
cardioplegic arrest. After 60 min of reperfusion, coron-
ary blood flow decreased significantly (p < 0.05) in the
Custodiol group, but it increased in the Custodiol-N
group (Table 2. Figure 2A). Endothelium-dependent vaso-
dilatation after ACh was significantly (p < 0.05) reduced
both groups after 60 min of reperfusion in compari-
son to values before extracorporal circulation (Figure 2B).
Endothelium-independent vasodilatation after SNP showed
no significant differences over time or between groups
(data not shown).
Biochemical measurements
Plasma nitrate/nitrite and myeloperoxidase values did
not significantly differ between the groups at baseline.sure volume relationship (ESPVR) and (B) left ventricular preload
ass and 60 minutes of reperfusion. Relative changes of the slope
(D) left ventricular preload recruitable stroke work (PRSW) after
n as mean ± SEM. *p < 0.05 vs. Custodiol, #p < 0.05 vs. baseline.
Figure 2 Coronary vascular function. Baseline coronary blood flow (A) and (B) endothelium-dependent vasodilatation after acetylcholine (ACh,
10−7 mol) expressed as a percent change of baseline coronary blood flow. All values are given as mean ± SEM. *p < 0.05 vs. Custodiol, #p < 0.05
vs. baseline.
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in the traditional HTK group than in the Custodiol-N
group (Table 2). Furthermore, there was also lower level
of plasma nitrate/nitrite in the Custodiol group in com-
parison to the treatment group (Custodiol-N) after CPB
(Table 2).
Myocardial high energy phosphate content is listed in
Table 3. ATP values were significantly higher in the
Custodiol-N group after 60-min reperfusion than in the
Custodiol group (Table 3).
Discussion
We demonstrated the superiority of Custodiol-N above
Custodiol in terms of cardiac and endothelial function
after CPB in our clinically relevant canine model of
cardiopulmonary bypass.
Since the start of cardiac surgery in the 1950s, mul-
tiple techniques (hypothermia, crystalloid or blood cardi-
oplegic solutions, direction of introduction (antegrade or
retrograde) etc.) have been used to protect the heart
during the surgical requirement for elective global ische-
mia. However, no single method was unequivocally the
best. There is a clinical and experimental evidence of
IR injury after CPB. Even if cardiac dysfunction is not
always clinically remarkable after CPB, reduction ofTable 3 Myocardial high energy phophates
Custodiol Custodiol-N
ATP (μmol/g dry weight) 9.5 ± 1.5 12.8 ± 1.0*
ADP (μmol/g dry weight) 5.6 ± 1.0 5.6 ± 0.5
AMP (μmol/g dry weight) 1.5 ± 0.3 1.7 ± 0.3
Myocardial levels of adenosine triphosphate (ATP), adenosine diphosphate
(ADP) and adenosine monophosphate (AMP) are shown after cardiopulmonary
bypass in both groups. *: p < 0.05 vs. Custodiol.myocardial contractility may occur as described in a
human study using pressure–volume relationships [15].
We could also show in our previous canine studies, that
myocardial dysfunction was developed after the adminis-
tration of Custodiol using a sensitive pressure-volume
conductance catheter [16].
The new cardioplegic solution (Custodiol-N) was
modified in 4 important points to enhance the protective
capacity of the Custodiol solution: 1, the addition of
iron-chelators (desferoxamine and the new, membrane-
permeable LK-614) to reduce iron-dependent injury 2,
reduction of chloride concentration to reduce chloride-
induced injury 3, addition of cardioprotective amino
acids (L-Arginin: NO-precursor to improve coronary
blood flow; glycine and alanine to stabilize the plasma
membrane) 4, partially substitution of histidine by N-
α-acetyl-L-histidine to inhibit the histidine-induced
cytotoxicity.
The combination of hypothermia and the potassium-
induced cardiac arrest represent the basis concept of
cold crystalloid cardioplegic solutions. However, present
studies clearly demonstrated that cold storage activates
specific cardiac injury processes; production of ROS trig-
gered by a cold-induced rise of physiologically negligible
cellular pool of the cellular cheletable iron, which inhibit
strongly cardiac and endothelial function since redox-
active iron ions convert ROS of low toxicity into highly
reactive species such as hydroxyl radicals [17,18]. Rauen
and co-workers determined the chelatable iron pool in
cultured rat hepatocytes and showed that at low
temperature the chelatable iron pool rapidly increased
and remained elevated for some hours [19]. In a further
investigation, Rauen et al. demonstrated the effectiveness
of a non-permeable iron-chelator deferoxamine and a
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iron-dependent cold injury [8].
Recently, a new, iron-independent component of cold
induced injury has also been described. When the stronger
iron-dependent component was inhibited with iron chela-
tors, the previously overshadowed chloride-dependent in-
jury became the limiting factor of cell survival. The new
solution (Custodiol-N) contains only 30 mM of chloride
because this concentration was sufficient to inhibit the
iron-independent component of cold induced injury in
cultured rat hepatocyte; there was no need to eliminate
chloride completely from the medium [7].
An experimental study clearly showed that application
of L-arginine as a substrate of eNOS can improve postis-
chemic blood flow and decrease leukocyte adhesion [20].
Moreover, a recent human study described that applica-
tion of L-arginin into the cardioplegic solution improved
left ventricular diastolic function [21]. Two amino acids,
alanine and glycine, are also included in Custodiol-N in
order to decrease the sodium accumulation during cold
ischemia and to stabilize the plasma membrane [12].
Side effects of using Custodiol solution were previously
also described (8). The main component of Custodiol, his-
tidine, is an excellent physiological buffer. However, Rauen
et al. demonstrated that histidine has a potential negative
effect on cell survival during cold ischemia (called as
preservation solution toxicity) [8]. With the use of iron
chelators (deferoxamine and LK-614), histidine toxicity
was strongly inhibited [8,13,22]. They also found that a
histidine-derivative, N-acetylhistidine exerted almost no
toxicity [8,13]. To prevent the injury caused by histidine,
N-acetylhistidine was added into the new Custodiol-N.
Radovits et al. [13] reported in an in vitro experiment a
significantly better endothelium protection with an N-
acetylhistidine containing solution (without any additives)
when compared to Custodiol.
The new cardioplegic solution (Custodiol-N) has already
been showed largely improved liver, lung and heart preser-
vation in different experimental studies [9-11,14]. Based
on the results of these studies we have tested the effect of
Custodiol-N on cardiac and endothelial function in a clin-
ically relevant large animal model. In this study, we inves-
tigated global myocardial performance and endothelial
function and metabolic parameters of the heart after a
60 minutes cardioplegic arrest. The clinically remarkable
parameters such as CO and MAP were unchanged after
CPB in both groups. However, we could demonstrate that
Custodiol-N is more effective than Custodiol at improving
the sensitive, load-independent index of left ventricular
contractility (ESPVR, PRSW) after hypothermic cardio-
plegic arrest and reperfusion. In particular, the PRSW of
the left ventricle in the Custodiol-N group remained prac-
tically unchanged when compared with the baseline to
60-minute reperfusion values (Figure 1).To prove whether the Custodiol-N reduce ROS-
generation, we also measured biochemical parameter of
heart such as plasma myeloperoxidase and plasma ni-
trite/nitrate level. The increased level of nitrite may be
explained as a result of better cardioprotection. Plasma
nitrite in blood has been widely used as an index of
endothelial NO synthase activity as routine indirect
measures of NO levels [23]. Myeloperoxidase (MPO) is
mainly released by neutrophil granulocytes, charac-
terised by powerful pro-oxidative properties [24]. MPO
catalyzes the conversion of chloride and hydrogen perox-
ide to hypochlorite and is secreted during inflammatory
response. As hypochlorite is extremely toxic to mamma-
lian cells, it causes tissue degradation and DNA break-
age. In addition, MPO consumes endothelial-derived
NO, thereby reducing NO bioavailability and impairing
its vasodilating and anti-inflammatory properties. As
shown by the metabolic values, application of new iron-
chelators and N-acetyl-L-histidine into Custodiol-N
seems to represent an optimal cardioprotection in
compared to Custodiol, because hearts of this group
showed the best recovery of energy charge potential
and cardiac performance. In addition, the increased
ATP level in the Custodiol-N group is also a sign of a bet-
ter cardioprotection.
Cardioplegic solutions were originally designed to
protect the myocardium, however at that time the pro-
tection of the vasculature, and more importantly, the
endothelium, was not an objective. Recently, Radovits
et al. [13] demonstrated the inability of Custodiol solu-
tion to offer a reasonable protection and preservation of
endothelial function after long-term ischemic storage.
Despite the importance of coronary endothelium few
investigators examined the effect of Custodiol on endo-
thelial function [25]. In the present study we measured
in vivo coronary blood flow before and after 60-min
reperfusion. After 60-min reperfusion the basal CBF
remained unchanged in the Custodiol-N group while in
the Custodiol group decreased significantly when com-
pared to the baseline level (Figure 2).
Conclusions
In conclusion, our large animal study provides evidence
that the new, L-arginin and N-α-acetyl-L-histidine-
enriched, chloride-poor, iron-chelator-enhanced cardio-
plegic solution (Custodiol-N) allows superior cardiac
and endothelial protection compared to Custodiol after
hypothermic cardiac arrest. The observed protective ef-
fects imply that the Custodiol-N could be the next gen-
eration cardioplegic solution in the protection against
ischemia-reperfusion injury in cardiac surgery.
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